Skip to main content
. Author manuscript; available in PMC: 2016 Sep 5.
Published in final edited form as: Mol Cell Endocrinol. 2015 May 21;412:226–238. doi: 10.1016/j.mce.2015.05.008

Figure 3.

Figure 3

Regulation of Xlr5c-like mRNA in periovulatory granulosa cells in vitro A) Granulosa cells obtained from rat preovulatory ovaries (48 h after PMSG) were cultured in medium alone (Control) or with hCG (1 IU/ml) for 0, 4, 8, 12, 24 h. B) Preovulatory granulosa cells were cultured for 8 h in medium alone (Vehicle, Veh) or with hCG (1 IU/ml), FSK (PKA agonist; 10 μM), PMA (PKC agonist; 20 nM), FSK (10 μM) + PMA (20 nM). C) Preovulatory granulosa cells were cultured for 8 h in medium alone (Veh), or with H89 (PKA inhibitor; 10 μM), GF109203X (PKC inhibitor; 1 μM) in the absence or presence of hCG (1 IU). D) Granulosa cells were cultured for 8 h in medium alone (Veh) or with LY294002 (P13K inhibitor; 25 μM), SB2035850 (p38 inhibitor; 25 μM), PD98059 (MEK inhibitor; 20 μM) in the absence or presence of hCG (1 IU/ml). E) Preovulatory granulosa cells were cultured in medium alone (Veh) or with cyclohexamide (1 μg/ml, CHX) in the presence or absence of hCG (1 IU/ml). F) Granulosa cells were cultured in medium alone (Veh) or with RU486 (PGR antagonist; 1 μM), MPA (synthetic progestin, 10 μM) and DEX (dexamethasone, synthetic glucocorticoid, 10 μM) in the absence or presence of hCG. The level of Xlr5c-like mRNA was measured by real-time PCR (mean ± SEM; n=3 experiments). Bars with no common superscripts in each panel are significantly different (p < 0.05).